GLP-1 Drugs for Heart Failure: Mechanisms, Evidence, and Clinical Potential | Research

The takeaway

Review examines the mechanisms and evidence for GLP-1 receptor agonists in heart failure, covering both direct cardiac effects and indirect benefits through weight loss and metabolic improvement.

Multi-mechanism cardiac benefit
GLP-1 drugs help the failing heart through direct protection, reduced inflammation, better metabolism, and weight loss combined

What the researchers found

GLP-1 drugs benefit heart failure through multiple mechanisms: direct cardiac protection, anti-inflammation, improved cardiac metabolism, weight loss, and vascular function improvement.

Why it matters

Heart failure is a leading cause of hospitalization and death. GLP-1 drugs are proving to be among the most important new heart failure treatments, especially for the common but hard-to-treat HFpEF subtype.

The numbers in context

Specific trial results are discussed in the full review. Cardiovascular outcome trials initially showed positive signals for heart benefits.

How the study worked

Review of mechanisms and clinical evidence for GLP-1 receptor agonists in heart failure management.

Who was studied

Heart failure patients, particularly those with HFpEF and comorbid obesity or diabetes

What this study cannot tell us

Some mechanistic evidence is preclinical. Heart failure subtypes may respond differently to GLP-1 drugs. The relative contribution of weight loss vs direct cardiac effects is debated.

How to read the evidence

Strong evidence: review of established mechanisms and clinical trial data, including the landmark SELECT and STEP-HFpEF trials.

When this study was published

Published in 2025. Incorporates the latest clinical trial evidence for GLP-1 drugs in heart failure.

The bigger picture

The SELECT and STEP-HFpEF trials have established GLP-1 drugs as cardiovascular medicines, not just metabolic drugs. This review synthesizes the mechanistic basis for their cardiac benefits, supporting their integration into heart failure management guidelines.

Questions still open

Will GLP-1 drugs be approved specifically for heart failure treatment?
Do direct cardiac GLP-1 effects or weight loss contribute more to heart failure improvement?
Should all heart failure patients with obesity receive GLP-1 drugs?

Common questions

Can GLP-1 drugs help with heart failure?

Yes — clinical trials show GLP-1 drugs like semaglutide improve heart failure outcomes, especially in patients with obesity. They work through multiple mechanisms including direct heart protection, reduced inflammation, and weight loss that decreases cardiac strain.

Which heart failure patients benefit most from GLP-1 drugs?

Current evidence is strongest for heart failure with preserved ejection fraction (HFpEF) in patients with obesity. GLP-1 drugs address the metabolic and inflammatory drivers of this common heart failure subtype.

Read the original research

Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates.

Cardiac failure review, 11, e28

View on PubMed ↗Publisher’s paper ↗

Citation

Abdelhamid, Magdy; Abdrabou, Mostafa M; Faris, Emanuel; El Kafas, Sameh; Hosny, Mohamed; Hassan, Ahmed. (2025). Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates.. Cardiac failure review, 11, e28. https://doi.org/10.15420/cfr.2025.17